EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Associations between lipoprotein(a), oxidized phospholipids, and extracoronary vascular disease

Tiffany R Bellomo, Yuxi Liu, Thomas C Gilliland, Hannah Miksenas, Sara Haidermota, Megan Wong, Xingdi Hu, Joaquim Rosado Cristino, Auris Browne, Jorge Plutzky, Sotirios Tsimikas, James L Januzzi und 1 weitere

Journal of Lipid Research · 2024

DOI: 10.1016/j.jlr.2024.100585 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Lipid Research, 2024. Verfasst von Tiffany R Bellomo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Vascular and Endovascular Surgery, Massachusetts General Hospital, Boston, MA, USA. Hauptthemen laut MEDLINE: Lipoprotein(a), Phospholipids, Oxidation-Reduction. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, Novartis Pharmaceuticals Corp.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The roles of lipoprotein(a) [Lp(a)] and related oxidized phospholipids (OxPLs) in the development and progression of coronary disease is known, but their influence on extracoronary vascular disease is not well-established. We sought to evaluate associations between Lp(a), OxPL apolipoprotein B (OxPL-apoB), and apolipoprotein(a) (OxPL-apo(a)) with angiographic extracoronary vascular disease and incident major adverse limb events (MALEs). Four hundred forty-six participants who underwent coronary and/or peripheral angiography were followed up for a median of 3.7 years. Lp(a) and OxPLs were measured before angiography. Elevated Lp(a) was defined as ≥150 nmol/L. Elevated OxPL-apoB and OxPL-apo(a) were defined as greater than or equal to the 75th percentile (OxPL-apoB ≥8.2 nmol/L and OxPL-apo(a) ≥35.8 nmol/L, respectively). Elevated Lp(a) had a stronger association with the presence of extracoronary vascular disease compared to OxPLs and was minimally improved with the addition of OxPLs in multivariable models. Compared to participants with normal Lp(a) and OxPL concentrations, participants with elevated Lp(a) levels were twice as likely to experience a MALE (odds ratio: 2.14, 95% confidence interval: 1.03, 4.44), and the strength of the association as well as the C statistic of 0.82 was largely unchanged with the addition of OxPL-apoB and OxPL-apo(a). Elevated Lp(a) and OxPLs are risk factors for progression and complications of extracoronary vascular disease. However, the addition of OxPLs to Lp(a) does not provide additional information about risk of extracoronary vascular disease. Therefore, Lp(a) alone captures the risk profile of Lp(a), OxPL-apoB, and OxPL-apo(a) in the development and progression of atherosclerotic plaque in peripheral arteries.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lipoprotein(a)PhospholipidsOxidation-ReductionHumansMaleFemaleMiddle AgedAgedVascular Diseases

Stichwörter der Autor:innen

lipidlipoprotein(a)peripheral angiographyperipheral artery disease

Substanzen

Lipoprotein(a)Phospholipids

Autor:innen und Institutionen

  • Division of Vascular and Endovascular Surgery, Massachusetts General Hospital, Boston, MA, USA.
  • Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT,…
  • Novartis Pharmaceuticals Corporation, Novartis, East Hanover, NJ, USA.
  • Division of Cardiology, Brigham and Women's Hospital, Boston, Harvard Medical School, Boston, MA, USA.
  • Sulpizio Cardiovascular Center, University of California San Diego, La Jolla, CA, USA.

Förderung

  • NHLBI NIH HHS
  • NIDDK NIH HHS
  • Novartis Pharmaceuticals Corp
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Heart Lung and Blood Institute
  • Massachusetts General Hospital
  • Novartis
  • Fondation Leducq

Zitieren

APA

Bellomo, T. R., Liu, Y., Gilliland, T. C., Miksenas, H., Haidermota, S., Wong, M., Hu, X., Cristino, J. R., Browne, A., Plutzky, J., Tsimikas, S., Januzzi, J. L., & Natarajan, P. (2024). Associations between lipoprotein(a), oxidized phospholipids, and extracoronary vascular disease. Journal of Lipid Research. https://doi.org/10.1016/j.jlr.2024.100585

Vancouver

Bellomo TR, Liu Y, Gilliland TC, Miksenas H, Haidermota S, Wong M, et al. Associations between lipoprotein(a), oxidized phospholipids, and extracoronary vascular disease. Journal of Lipid Research. 2024. doi:10.1016/j.jlr.2024.100585

BibTeX
@article{Bellomo2024,
  author = {Bellomo, Tiffany R and Liu, Yuxi and Gilliland, Thomas C and Miksenas, Hannah and Haidermota, Sara and Wong, Megan and Hu, Xingdi and Cristino, Joaquim Rosado and Browne, Auris and Plutzky, Jorge and Tsimikas, Sotirios and Januzzi, James L and Natarajan, Pradeep},
  title = {Associations between lipoprotein(a), oxidized phospholipids, and extracoronary vascular disease},
  journal = {Journal of Lipid Research},
  year = {2024},
  doi = {10.1016/j.jlr.2024.100585}
}
Kostenlos starten →